
Pharmaceutical retailer Walgreens Boots Alliance, Inc. (WBA) warned of facing lower sales persisting into next year due to inflation affecting consumers’ spending. The end of the COVID emergency led to a sharp drop in the sale of vaccines and tests, according to the company’s executives.
WBA increased the target of an ongoing cost-cutting program to counter those pressures. The company lowered its full-year adjusted EPS guidance from $4.45-$4.65 to $4.00-$4.05.